Two-stage randomization designs in drug development

Statistics in Medicine

Volumn 27, Issue 21, 2008, Pages 4161-4174

  Wolbers, Marcel ^a   Helterbrand, Jeffrey D ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b GENENTECH INC   (United States)

Author keywords

Cox regression; Inverse probability weighting; Maintenance; Time to event; Two stage randomization design

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESEARCH; FACTORIAL DESIGN; INFORMED CONSENT; KAPLAN MEIER METHOD; MAINTENANCE THERAPY; MATHEMATICAL COMPUTING; MEDICAL DECISION MAKING; OUTCOMES RESEARCH; PROBABILITY; PROPORTIONAL HAZARDS MODEL; RANDOMIZATION; SAMPLE SIZE; SCORING SYSTEM; SIMULATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMPUTER SIMULATION; HUMANS; LYMPHOMA, NON-HODGKIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SAMPLE SIZE;

EID: 50849114508     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3309     Document Type: Article

References (21)

1. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. Journal of Clinical Oncology 2006; 24:3121-3127.
2. van Oers MHJ, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, Jack A, van't Veer M, Vranovsky A, Holte H, van Glabbeke M, Teodorovic I, Rozewicz C, Hagenbeek A. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108:3295-3301.
3. Forstpointner R, Unterhalt M, Dreyling M, Bock HP, Repp R, Wandt H, Pott C, Seymour JF, Metzner B, Hanel A, Lehmann T, Hartmann F, Einsele H, Hiddemann W. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108:4003-4008.
4. Thomas X, Raffoux E, de Botton S, Pautas C, Arnaud P, de Revel T, Reman O, Terre C, Corront B, Gardin C, Le QH, Quesnel B, Cordonnier C, Bourhis JH, Elhamri M, Fenaux P, Preudhomme C, Michallet M, Castaigne S, Dombret H. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia 2007; 21:453-461.
5. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, Lee EJ, Moore JO, Powell BL, Schiffer CA. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. New England Journal of Medicine 1995; 332: 1671-1677.
6. Murphy SA. An experimental design for the development of adaptive treatment strategies. Statistics in Medicine 2005; 24:1455-1481.
7. Lokhnygina Y, Helterbrand JD. Cox regression methods for two-stage randomization designs. Biometrics 2008; 63:422-428.
8. Lunceford JK, Davidian M, Tsiatis AA. Estimation of survival distributions of treatment policies in two-stage randomization designs in clinical trials. Biometrics 2002; 58:48-57.
9. Guo X, Tsiatis AA. Estimation of survival distributions in two-stage randomization designs with censored data. International Journal of Biostatistics 2005; 1:Article 1. Available at: http://www.bepress.com/ijb/vol1/iss1/1.
10. Wahed AS, Tsiatis AA. Optimal estimator for the survival distribution and related quantities for treatment policies in two-stage randomization designs in clinical trials. Biometrics 2004; 60:124-133.
11. Wahed AS, Tsiatis AA. Semiparametric efficient estimation of survival distributions in two-stage randomisation designs in clinical trials with censored data. Biometrika 2006; 93:163-177.
12. Horvitz DG, Thompson DJ. A generalization of sampling without replacement from a finite universe. Journal of the American Statistical Association 1952; 47:663-685.
13. Therneau TE, Grambsch TM. Modeling Survival Data: Extending the Cox Model. Springer: New York, 2001.
14. R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, 2006. Available from: www.R-project.org.
15. Binder DA. Fitting Cox proportional hazards models from survey data. Biometrika 1992; 79:139-147.
16. Schoenfeld DA. Sample-size formula for the proportional-hazards regression-model. Biometrics 1983; 39:499-503.
17. Mehta CR, Tsiatis AA. Flexible sample size considerations using information-based interim monitoring. Drug Information Journal 2001; 35:1095-1112.
18. Dmitrienko A, Offen WW, Westfall PH. Gatekeeping strategies for clinical trials that do not require all primary effects to be significant. Statistics in Medicine 2003; 22:2387-2400.
19. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo J, Jack A, Smith P. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105:1417-1423.
20. Hochster HS, Weller E, Ryan T, Habermann TM, Cascoyne R, Frankel SR, Hornig SJ. Results of E1496: a phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). Journal of Clinical Oncology 2004; 22(14S):6502.
21. Salles G. Study protocol: primary rituximab and maintenance (PRIMA) trial - a multicentre, phase III, open-label, randomized study in patients with advanced follicular lymphoma evaluating the benefit of maintenance therapy with rituximab (MabThera®) after induction of response with chemotherapy plus rituximab in comparison with no maintenance therapy. prima.gela.org, 2004.